Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 12/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600884 | 0.92 | GPBAR1 (0.38) | GPBAR1CETPTACR1SGMS1SGMS2 | |
| SCHEMBL1600292 | 0.92 | PTGDR2 (0.39) | GPBAR1CETPMGLLPTGER1PTGDR2 | |
| SCHEMBL1601777 | 0.90 | CETP (0.55) | CETPPTGDR2 | |
| SCHEMBL1600503 | 0.90 | CETP (0.41) | CETPTACR1SGMS1SGMS2MGLL | |
| SCHEMBL1599583 | 0.83 | CETP (0.48) | CETPPTGDR2 | |
| SCHEMBL1600836 | 0.82 | CETP (0.47) | CETPPTGDR2 | |
| SCHEMBL1601255 | 0.78 | CETP (0.45) | GPBAR1CETPPTGDR2 | |
| SCHEMBL1601446 | 0.77 | TACR1 (0.41) | GPBAR1TACR1MGLL | |
| SCHEMBL1600385 | 0.77 | MGLL (0.40) | MGLLPTGER1PTGDR2 | |
| SCHEMBL3559191 | 0.76 | GPBAR1 (0.54) | GPBAR1CETPTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | GPBAR1 46/4885CETP 3/4885TACR1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.